Literature DB >> 9794204

Cytokine transgene expression and promoter usage in primary CD34+ cells using particle-mediated gene delivery.

Z Q Ye1, P Qiu, J K Burkholder, J Turner, J Culp, T Roberts, N T Shahidi, N S Yang.   

Abstract

Induction or short-term transgenic expression of specific cytokines, growth factors, or other candidate therapeutic genes in hematopoietic progenitor or stem cells is potentially applicable to gene therapy for cancer. In this study, we explored the application of a gene gun technique, as an alternative to viral vectors, for ex vivo gene transfer into and transient gene expression in highly enriched CD34+ cells derived from human umbilical cord blood. Twenty-four hours posttransfection, 32.6 to 1500 pg/l x 10(6) CD34+ cells of transient gene expression was routinely obtained for specific cytokine and reporter genes. Transgene expression at the single-cell level was revealed by X-Gal staining of lacZ cDNA-transfected CD34+ cells. Expression of four candidate therapeutic genes, namely human granulocyte-macrophage colony-stimulating factor, tumor necrosis factor alpha, interleukin 2, and interferon gamma, was detectable for 4 to 7 days in CD34+ cells. A human elongation factor 1alpha promoter/intron 1 transcription unit was identified as a strong cellular promoter for CD34+ cells, exhibiting strength similar to that of the commonly employed cytomegalovirus immediate-early promoter. These results suggest that the nonviral, gene gun technique offers an efficient alternative approach for transient transgenic studies of hematopoietic cells and may provide new possibilities for certain cancer gene therapy strategies using CD34+ cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794204     DOI: 10.1089/hum.1998.9.15-2197

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  4 in total

1.  Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system.

Authors:  Teiko Sumiyoshi; Nathalia G Holt; Roger P Hollis; Shundi Ge; Paula M Cannon; Gay M Crooks; Donald B Kohn
Journal:  Hum Gene Ther       Date:  2009-12       Impact factor: 5.695

2.  Strategies to insulate lentiviral vector-expressed transgenes.

Authors:  Ali Ramezani; Robert G Hawley
Journal:  Methods Mol Biol       Date:  2010

3.  Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter.

Authors:  T R Bauer; E M Olson; Y Huo; L M Tuschong; J M Allen; Y Li; T H Burkholder; D W Russell
Journal:  Gene Ther       Date:  2011-01-13       Impact factor: 5.250

4.  Lentiviral vectors incorporating a human elongation factor 1alpha promoter for the treatment of canine leukocyte adhesion deficiency.

Authors:  E J R Nelson; L M Tuschong; M J Hunter; T R Bauer; T H Burkholder; D D Hickstein
Journal:  Gene Ther       Date:  2010-02-18       Impact factor: 5.250

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.